Investor's Business Daily on MSN
How S&P 500 giant Pfizer is tackling hard-to-treat cancers
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
May 29 (Reuters) - China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and ...
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions ...
Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...
Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...
A cancer diagnosis changes how people measure time. This article explores how advances in oncology research, precision ...
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results